Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher-dose nusinersen after risdiplam in later-onset SMA
jRCT2051230096Phase 3Completed
- Sponsor
- Biogen
- Start
- May 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Primary endpoint: Change in total RULM score. Started May 2024; status: completed.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on jRCT2051230096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230096.